Orion Infusion’s Stock Price Surges By 46%

Industry: Healthcare & Pharma, Pharma, Stock Market
Company: Orion Infusion Ltd
Company Intelligence Tag: Business Insights

Orion Infusion has experienced a remarkable surge in its stock price, rising 46% in just one month to Tk 438 from Tk 299.2 on November 26, 2023. This unusual movement prompted the DSE to issue a show-cause notice to the company, inquiring about the reasons behind the surge.

Despite the notice, the stock price continued to climb, jumping an additional 6% on December 24. Analysts suggest that the surge may be linked to the company’s decision to issue rights shares, aiming to increase its paid-up capital to meet regulatory requirements. Orion Infusion’s board announced plans to issue one rights share against the existing two shares at Tk 20 each, including Tk 10 as a premium per share.

This move comes as the Bangladesh Securities and Exchange Commission (BSEC) urges small-cap companies to raise their paid-up capital to at least Tk 300 million. Investors are speculating on potential gains from the rights share issuance, driving the stock price higher.

Source for more details:

Related News

Stocks Rebound After Hitting Five-Year Low

May 21, 2025

On May 20, 2025, Bangladesh’s stock market rebounded from a five-year low as bargain hunters capitalized on undervalued shares. The DSEX rose 13 points (0.28%) to 4,789 in the first hour of trading. Blue-chip and Shariah indices also posted gains.

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Tk2000 Crore Raised By 24 Firms Now In Z And B Categories

April 24, 2025

Over the past seven years, 56 companies raised Tk5,178 crore through IPOs in Bangladesh, but 24 of them—collectively raising over Tk2,000 crore—have been downgraded to the Z and B categories due to poor financial performance.

Related News

Stocks Rebound After Hitting Five-Year Low

May 21, 2025

On May 20, 2025, Bangladesh’s stock market rebounded from a five-year low as bargain hunters capitalized on undervalued shares. The DSEX rose 13 points (0.28%) to 4,789 in the first hour of trading. Blue-chip and Shariah indices also posted gains.

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Tk2000 Crore Raised By 24 Firms Now In Z And B Categories

April 24, 2025

Over the past seven years, 56 companies raised Tk5,178 crore through IPOs in Bangladesh, but 24 of them—collectively raising over Tk2,000 crore—have been downgraded to the Z and B categories due to poor financial performance.

BUSINESSMONITOR

Connect with


Dont Have Account? Please register Here